SCHEMBL2962664

SCHEMBL2962664

CC(C)(C)OC(=O)C(N)CCl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.37
NOS3 P29474 1/20 0.37
NOS2 P35228 1/20 0.37
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
LTA4H P09960 1/20 0.35
CYP3A4 P08684 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
NFKB1 P19838 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC7A5 Q01650 1/20 0.33
PMP22 Q01453 1/20 0.33
NLRP3 Q96P20 1/20 0.33
FAAH O00519 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
DGAT1 O75907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26627409 0.83 NOS1 (0.39) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL3294154 0.82 NOS1 (0.42) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL569252 0.82 NOS1 (0.39) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL30458009 0.80 NOS1 (0.38) NOS1NOS3NOS2LMNAKMT2A
Hydrochloric Acid SCHEMBL20243055 0.80 NOS1 (0.38) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL34507 0.80 NOS1 (0.38) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL1952044 0.80 NOS1 (0.38) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL8350648 0.80 NOS1 (0.38) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL186690 0.80 NOS1 (0.38) NOS1NOS3NOS2LMNAKMT2A
SCHEMBL186691 0.80 NOS1 (0.38) NOS1NOS3NOS2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3712127-A1 NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 Deutsches Krebsforschungszentrum (DE) 2020-09-23 EP disclosed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP disclosed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US disclosed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040961-A1 Furanopyrimidines TYMS, IDO1, NFATC1 NOS1 313/4885NOS3 1138/4885NOS2 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.